ANNA Home Page
ANNA CE Link
HDCN Home Page
HDCN Registration Link

If you dont have an Acrobat Reader installed on your computer, you may download it for free from the link below:


The Benefits of IV Iron Therapy in Treating Anemia in Patients With Renal Disease and Comorbid Cardiovascular Disease
(Vol 32/No. 2. On-line test expires: 4/20/2007)
To receive continuing education credit, you must read the information in this article and take an on-line post test and fill out an on-line program evaluation form. The certificate will then be generated for you as a .pdf file which you can print out locally on your computer.

CE Certification by ANNA requires a handling charge that must be paid by credit card. Pricing information is available by clicking on the "Post-Test Evaluation" link below.
  DOWNLOAD TEST ARTICLE
Please download and print the PDF file below:
  AUTHOR
Ajay K. Singh, MB, MRCP,
Ajay K. Singh, MB, MRCP, is Clinical Chief, Renal Division Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, MA.
Paula Hertello
Paula Hertello is Project Manager, Renal Division Brigham and Women’s Hospital, Boston, MA.
  OUTLINE

It is important for nephrology nurses to understand the relationship that exists between renal disease, cardiac disease, and anemia. Even mild cases of chronic kidney disease (CKD) have been associated with an increase in adverse cardiovascular outcomes. And anemia, which can result from both CKD and congestive heart failure, has been shown to exacerbate the adverse consequences of these conditions. An early, aggressive correction of anemia in patients with CKD can be implemented to break this cycle and stop disease progression. Studies have shown that anemia correction improves both cardiac and renal function and can result in increased hemoglobin levels, decreased number of hospital days, and improved quality of life. An effective strategy for managing anemia in patients with renal disease and comorbid cardiovascular disease includes the administration of both recombinant human erythropoietin and intravenous iron. In addition, the nephrology nurse plays an integral role in managing anemia and improving outcomes in these patients. Therefore, the nephrology nurse should have an increased awareness of the link between anemia and renal/cardiac disease as well as available treatment options.

  GET YOUR CE CERTIFICATE
Take on-line Quiz:
  CE RELATED INFORMATION
This offering for 1.8 contact hours is being provided by the American Nephrology Nurses’ Association (ANNA), which is accredited as a provider and approver of continuing education in nursing by the American Nurses’ Credentialing Center-Commission on Accreditation (ANCCCOA). This educational activity is approved by most states and specialty organizations that recognize the ANCC-COA accreditation process. ANNA is an approved provider of continuing education in nursing by the California Board of Registered Nursing, BRN Provider No. 00910.

  EDUCATIONAL OBJECTIVES

Goal:
To understand the association among anemia, renal disease, and cardiac disease and the benefits of IV iron therapy in managing patients with anemia of renal/cardiac disease

Objectives:
1. Discuss the relationship among anemia, renal disease, and cardiac disease.
2. Identify the benefits of IV iron therapy in managing the anemia of renal/ cardiac disease.
3. Describe the nephrology nurse’s role in treating this patient population.

AUTHOR DISCLOSURE STATEMENT
Ajay K. Singh, MB, MRCP, has no conflicts of interest to disclose.
Paula Hertello has no conflicts of interest to disclose.

 ANNA and HDCN CE POLICY STATEMENTS

The CE policy and disclosure statements of the American Nephrology Nurses' Association are given in detail on the Symposium Home Page. The CE policy statements of HDCN are listed on this page.